Amgen (AMGN) announces positive results from a study of its cholesterol-fighting human...

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (AMGN) announces positive results from a study of its cholesterol-fighting human monoclonal antibody AMG 145. The treatment reduces so-called bad cholesterol by up to 81%, according to data. Phase II results are due out later this year as Amgen tries to shoulder into the high-stakes Lipitor vs. generics battle.